Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

Chunxiang Jin, Rongrong Chen, Shan Fu, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7082.

https://doi.org/10.1182/blood-2024-201470

Published: 2024

Journal Articles

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

Wenxiao Li, Yongxian Hu, Mingming Zhang, Xinyi Lai, Mengyu Zhao, Shan Fu, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 7229.

https://doi.org/10.1182/blood-2024-209660

Published: 2024

Journal Articles

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Yongxian Hu, Mingming Zhang, Shan Fu, Ruimin Hong, Jiazhen Cui, Simao Huang, Min Gao, Daojun Bai, Jingjing Ren, Xingbing Wang, Yugang Guo, Li Tang, He Huang

Blood (2024) 144 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2024-207694

Published: 2024

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Yongxian Hu, Yali Zhou, Mingming Zhang, Shan Fu, Yong Yu, Ming Gao, Ruimin Hong, Houli Zhao, Lu Han, Jiangtao Ren, He Huang

Blood (2024) 144 (Supplement 1): 921.

https://doi.org/10.1182/blood-2024-207322

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Yongxian HU, Guoqing Wei, Shan Fu, Pingnan Xiao, Jingjing Feng, Mingming Zhang, Xingbing Wang, Dongrui Wang, Jun Li, He Huang

Blood (2023) 142 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2023-189052

Published: 2023

Journal Articles

Ultra-Low-Dose of Decitabine with Venetoclax As Induction and Consolidation Therapy for Elderly or Frail Newly Diagnosed Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Patients

Weiyan Zheng, Shan Fu, Xuepin Luo, Yuanyuan Zhu, He Huang

Blood (2023) 142 (Supplement 1): 5934.

https://doi.org/10.1182/blood-2023-191155

Published: 2023

Journal Articles

Newly Dignosed Early T-Cell Precursor Acute Lymphoblastic Leukemia Successfully Treated with Venetoclax Combined with DA and IA Regime

Xuepin Luo, Shan Fu, Weiyan Zheng

Blood (2023) 142 (Supplement 1): 5888.

https://doi.org/10.1182/blood-2023-191324

Published: 2023

Journal Articles

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood (2023) 142 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2023-185697

Published: 2023

Journal Articles

Prognostic Risk Factors for Patients with Candida Tropicalis Fungemia Infections and Hematological Malignancies

Haisu Zhao, Shan Fu, Yuanyuan Zhu, He Huang, Weiyan Zheng

Blood (2023) 142 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2023-189437

Published: 2023

Journal Articles

C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription

Mengbao Du, Mowang Wang, Meng Liu, Shan Fu, Yu Lin, Jian Yu, Xiaohong Yu, He Huang, Haowen Xiao, Limengmeng Wang

Blood (2022) 140 (Supplement 1): 3077–3079.

https://doi.org/10.1182/blood-2022-166249

Published: 2022

Journal Articles

CEBPA Gene Mutations Interfere with Expressions of NKG2D Ligands Ulbps in AML Cells and Modulate Their Susceptibility to NK-Mediated Lysis

Meng Liu, Limengmeng Wang, PhD, Huafang Wang, Shan Fu, He Huang, Haowen Xiao

Blood (2019) 134 (Supplement_1): 1257.

https://doi.org/10.1182/blood-2019-129899

Published: 2019

Journal Articles

Restoration of CCAAT Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block and All-Trans Retinoic Acid Resistance in Human Acute Promyelocytic Leukemia NB4-R1 Cells

Limengmeng Wang, Haowen Xiao, Xing Zhang, Weichao Liao, Shan Fu, He Huang, MD PhD

Blood (2015) 126 (23): 1238.

https://doi.org/10.1182/blood.V126.23.1238.1238

Published: 2015

Journal Articles

Impaired NK Cells Cytotoxicity Against Activated, Alloreactive Donor T Cells in aGVHD and Ability of Dasatnib to Restored the Gvhd-Regulation Function of NK Cells

Lixia Sheng, Huarui Fu, Yongxian Hu, Shan Fu, Yamin Tan, Yi Luo, Xiaoyu Lai, Jimin Shi, Ying He, He Huang, MDPhD

Blood (2014) 124 (21): 3906.

https://doi.org/10.1182/blood.V124.21.3906.3906

Published: 2014

Journal Articles

Bone Marrow Microenvironment Is a New Therapeutic Target of Ruxolitinib in Myeloproliferative Neoplasm

Kaimin Hu, Lou Lixia, Lizhen Liu, Binsheng Wang, Shan Fu, Xiaohong Yu, He Huang, MD PhD

Blood (2014) 124 (21): 2930.

https://doi.org/10.1182/blood.V124.21.2930.2930

Published: 2014

Journal Articles

The Key Role of PML in IFN-α Induced Cellular Senescence of Human Mesenchymal Stromal Cells

Shan Fu, Jieping Wei, Binsheng Wang, He Huang, MDPhD

Blood (2014) 124 (21): 3611.

https://doi.org/10.1182/blood.V124.21.3611.3611

Published: 2014

Journal Articles

CEBPA Gene Different Mutants Play Distinct Impacts On Tumor Suppressor Function Of C/EBP-Alpha and Bone Marrow Stromal Cells

Haowen Xiao, Wang Li-Mengmeng, Binsheng Wang, Chong Wang, Lifei Zhang, Shan Fu, Yebo Wang, He Huang

Blood (2013) 122 (21): 2519.

https://doi.org/10.1182/blood.V122.21.2519.2519

Published: 2013

NARROW

Prior ASCT Has a Negative Impact on Outcomes in Relapsed/Refractory Multiple Myeloma Patients after BCMA CAR-T Therapy

APRIL CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma: A Phase I Clinical Trial

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2 ) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Ultra-Low-Dose of Decitabine with Venetoclax As Induction and Consolidation Therapy for Elderly or Frail Newly Diagnosed Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Patients

Newly Dignosed Early T-Cell Precursor Acute Lymphoblastic Leukemia Successfully Treated with Venetoclax Combined with DA and IA Regime

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Prognostic Risk Factors for Patients with Candida Tropicalis Fungemia Infections and Hematological Malignancies

C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription

CEBPA Gene Mutations Interfere with Expressions of NKG2D Ligands Ulbps in AML Cells and Modulate Their Susceptibility to NK-Mediated Lysis

Restoration of CCAAT Enhancer Binding Protein Alpha P42 Overcomes Myeloid Differentiation Block and All-Trans Retinoic Acid Resistance in Human Acute Promyelocytic Leukemia NB4-R1 Cells

Impaired NK Cells Cytotoxicity Against Activated, Alloreactive Donor T Cells in aGVHD and Ability of Dasatnib to Restored the Gvhd-Regulation Function of NK Cells

Bone Marrow Microenvironment Is a New Therapeutic Target of Ruxolitinib in Myeloproliferative Neoplasm

The Key Role of PML in IFN-α Induced Cellular Senescence of Human Mesenchymal Stromal Cells

CEBPA Gene Different Mutants Play Distinct Impacts On Tumor Suppressor Function Of C/EBP-Alpha and Bone Marrow Stromal Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only